Billionaire Halvorsen Reveals Another New Energy Play, Mandel Buys Lululemon Athletica Inc. (LULU), Plus Two Other Bullish Moves

To conclude our discussion, let’s take a thorough look at the 13G filing submitted by Jason Karp’s hedge fund firm. Tourbillon Capital Partners L.P. reported owning 2.33 million shares of Radius Health Inc. (NASDAQ:RDUS), which represent 5.4% of the company’s outstanding common stock. This is up by 1.33 million shares from the stake Tourbillon disclosed owning as of the end of September. The shares of the science-driven biopharmaceutical company are down by 24% over the past year, which might have created clear entry points for some investors. The company mainly focuses on developing therapeutics for patients with advanced osteoporosis, which causes bones to become brittle and fragile due to loss of tissue, as well as other endocrine-mediated diseases such as hormone responsive cancers. Radius Health Inc. (NASDAQ:RDUS)’s lead product candidate is abaloparatide, which is a bone anabolic for the reduction of fracture risk in postmenopausal women with severe osteoporosis. The company’s clinical product portfolio also comprises the investigational drug RAD1901, which is a selective estrogen receptor degrader, and RAD140, a non-steroidal selective androgen receptor modulator. The number of hedgies from our system with stakes in the biopharmaceutical company remained flat during the third quarter at 23.

Disclosure: None